

Impact Of Sustainable Financial Support Through Indian Cancer Society - Cancer Cure Fund (ICS-CCF) For Treatment Of Cancer Patients – A Model From A Developing Country

T. Vora¹, N. Khanna², A. Gokarn³, A. Gulia⁴, S. Gulia³, A. Rawat⁵, N. Halady⁵, U. Thorat⁶, S. Banavali¹

¹Tata Memorial Centre- Harni Bhatha National Institute, Pediatric/Medical Oncology, Mumbai, India. ²Tata Memorial Centre- Harni Bhatha National Institute, Radiation Oncology, Mumbai, India. ³Tata Memorial Centre- Harni Bhatha National Institute, Medical Oncology, Mumbai, India. ⁴Tata Memorial Centre- Harni Bhatha National Institute, Orthopedic/Surgical Oncology, Mumbai, India. ⁵Indian Cancer Society, Director- Cancer Care, Mumbai, India. ⁶Indian Cancer Society, Chairperson- Governing Advisory Council- Cancer Care, Mumbai, India.

Scenario - Methods


Every year in a single tertiary care centre ~ 60000 new cancer registrations

Leading cause of TR&A – Financial Constraints

Goal – Single source of substantial financial help to significant number of patients through a model that is sustainable, near to home

HDFC-AMC with ICS – 3 phased MFS (2011-2019)

Outcome analysis of patients supported from 2011 – 2014 – long term outcomes




Till 31st December 2018, 6805 patients from 34/36 States & UTI, have received sanctions of Rs. 196.78 crore (~US \$ 28 Millions)




Time of Registrations to Date of Application

Median 54 Days



Date of Registration to Date of Last Follow up/Event or Cancer

Median Follow-up - 4.3 years
Median Follow up of Alive Patients - 5.7 years



Processes



Results & Conclusions

At a median follow up of 5.7 years - > 50% of patients have been cured of Cancer.

The lost to follow up rates varied widely between institutes (5.9% - 58%)

On average 46.5% of total treatment cost supported by ICS-CCF (Range 31% - 62%) across institutes and diagnoses

ICS-CCF has significantly impacted lives of substantial number of cancer patients Pan-India.

This sustainable model of financial aid for cancer patients can be replicated across resource constrained countries.